To assess the neuroprotective potential of melatonin in apoptotic neuronal cell death, we investigated the efficacy of melatonin in serum-free primary neuronal cultures of rat cortex by using three different models of caspase-dependent apoptotic, excitotoxin-independent neurodegeneration and compared it to that in necrotic neuronal damage. Neuronal apoptosis was induced by either staurosporine or the neurotoxin ethylcholine aziridinium (AF64A) with a delayed occurrence of apoptotic cell death (within 72 h). The apoptotic component of oxygen-glucose deprivation (OGD) unmasked by glutamate antagonists served as a third model. As a model for necrotic cell death, OGD was applied. Neuronal injury was quantified by LDH release and loss of metabolic activity. Although melatonin (0.5 mM) partly protected cortical neurons from OGD-induced necrosis, as measured by a significant reduction in LDH release, it was not effective in all three models of apoptotic cell death. In contrast, exaggeration of neuronal damage by melatonin was observed in native cultures as well as after induction of apoptosis. The present data suggest that the neuroprotectiveness of melatonin strongly depends on the model of neuronal cell death applied. As demonstrated in three different models of neuronal apoptosis, the progression of the apoptotic type of neuronal cell death cannot be withhold or is even exaggerated by melatonin, in contrast to its beneficial effect in the necrotic type of cell death.-Harms, C., Lautenschlager, M., Bergk, A., Freyer, D., Weih, M., Dirnagl, U., Weber, J. R., Hörtnagl, H. Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures. FASEB
Melatonin, the main secretory product of the pineal gland, is well known for its functional interactions with the neuroendocrine axis and with circadian rhythms. Very recently it has also been found to be a free radical scavenger and antioxidant (for reviews, see refs [1] [2] [3] . Neuroprotective effects of melatonin have been demonstrated mainly in models of neuronal cell death in which oxygen free radicals or excitotoxins are involved. In the N-methyl-4-phenylpyridinium and 6-hydroxydopamine (6-OHDA) models of Parkinson's disease, melatonin completely reversed the rises in lipid peroxidation products, the decrease in tyrosine hydroxylase in striatum and substantia nigra, and rescued dopamine neurons in culture (4 -7) . Melatonin also prevented kainate-induced neuronal cell death and reduced lipid peroxidation products in rats and mice in vivo (8 -10) . Furthermore, melatonin protects against glutamate-induced cell death in the clonal hippocampal cell line HT22 (11) , prevents delayed neuronal death induced by enhanced excitatory transmission in hippocampal pyramidal neurons in culture (12) , and rescues neuroblastoma cells exposed to toxic fragments of Alzheimer's ␤-amyloid (13) . An anticonvulsant activity of melatonin has been demonstrated against excitotoxin-induced seizures by quinolinate, kainate, and glutamate in mice and by iron or amygdala kindling in rats (14 -17) . The occurrence of increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats is in line with these findings (18) .
Besides the antioxidant potential, several other mechanisms are considered to be involved in the neuroprotection mediated by melatonin, including interactions with calmodulin (19, 20) and microtubular components (20) , blockade of increases in intracellular Ca 2ϩ levels (13) , maintenance of cellular glutathione homeostasis (21) , inhibition of activation of NF-B by cytokines such as tumor necrosis factor ␣ (22) , inhibition of the expression of inducible nitric oxide synthase at the transcriptional level (23) , and changes in gene expression of antioxidant enzymes (24) .
The aim of the present study was to answer the question of whether melatonin is also neuroprotective in the case of neuronal damage, which is not primarily related to oxidative stress or excitotoxicity. For this purpose, we investigated the efficacy of melatonin in primary neuronal cultures by using three different models of apoptotic, excitotoxinindependent neurodegeneration in comparison with necrotic neuronal damage. Oxygen-glucose deprivation (OGD) was applied as a model for excitotoxic and oxidative stress inducing cell damage. A protective effect of melatonin against hypoxia/reoxygenation has been reported in primary cultures of rat cortical neurons (25) and after transient forebrain ischemia in rats (26) . As a standard apoptotic model treatment with staurosporine was used. The mycotoxin staurosporine is believed to activate programmed cell death in virtually all cells (27) (28) (29) . It has also been shown to induce neuronal apoptosis in primary neuronal cultures (30, 31) . In addition, a model characterized by a delayed occurrence of apoptotic cell death induced by the neurotoxin ethylcholine aziridinium (AF64A) was applied. AF64A, initially introduced as a model of cholinergic hypofunction (for a recent review, see ref 32) , has been shown to initiate neuronal cell death in vivo and in vitro by activating mechanisms of apoptosis (33) . An involvement of glutamate in the neurotoxicity of AF64A has been excluded (34) . In primary neuronal cultures of various brain areas, AF64A induces neuronal cell death with a delay of 2-3 days (35) . The apoptotic component of OGD unmasked by glutamate antagonists (36) served as a third model.
MATERIALS AND METHODS

Materials
Melatonin, staurosporine, dimethyl sulfoxide (DMSO), N-tertbutyl-␣-phenylnitrone (PBN), dimethylthiourea (DMTU), MTT, and enzyme standard for kinetic lactate dehydrogenase (LDH) test were obtained from Sigma Chemie GmbH (Deisenhofen, Germany), neurobasal medium and supplement B27 from Life Technologies, Inc. (Eggenstein, Germany); modified Eagle's medium, phosphate-buffered saline (PBS), HEPES buffer, trypsin/EDTA, penicillin/streptomycin, Lglutamine, collagen-G, and poly-L-lysine from Biochrom (Berlin, Germany); multiwell plates from Falcon (Franklin Lakes, N.J.); the caspase inhibitor Z-VAD-FMK from Calbiochem-Novabiochem (Bad Soden/Taunus, Germany). AF64A was prepared from acetylethylcholine mustard (Research Biochemicals International, Natick, Mass.) according to Fisher et al. (37) .
Primary neuronal cell culture
Primary neuronal cultures of cerebral cortex were obtained from embryos (E16-E18) of Wistar rats (Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin, Berlin, Germany). Cultures were prepared according to Brewer (38) with the following modifications. Cerebral cortex was dissected, incubated for 15 min in trypsin/EDTA (0.05/ 0.02% w/v in PBS) at 36.5°C, rinsed twice with PBS and once with dissociation medium (modified Eagle's medium with 10% fetal calf serum, 10 mM HEPES, 44 mM glucose, 100 U penicillin ϩ streptomycin/ml, 2 mM L-glutamine, 100 IE insulin/l), dissociated by Pasteur pipette in dissociation medium, pelleted by centrifugation (at 210 g for 2 min at 21°C), redissociated in starter medium (neurobasal medium with supplement B27, 100 U penicillin ϩ streptomycin/ml, 0.5 mM L-glutamine, 25 M glutamate), and plated in 24-well plates or 6-well plates in a density of 200,000 cells per cm 2 . Wells were pretreated by incubation with poly-L-lysine (0.5% w/v in PBS) for 1 h at room temperature, then rinsed with PBS, followed by incubation with coating medium (dissociation medium with 0.03‰ w/v collagen G) for 1 h at 37°C, then rinsed twice with PBS before seeding cells in starter medium. Cultures were kept at 36.5°C and 5% CO 2 and fed beginning with the fourth day in vitro (DIV) with cultivating medium (starter medium without glutamate) by replacing half of the medium twice a week.
Injury paradigms
In all models the serum-free primary neuronal cultures were treated after 10 to 14 DIV. Condition of cells at various time points after treatment was determined morphologically by phase contrast microscopy.
AF64A (5-80 M) exposure was either for 5 h with subsequent rinsing and reapplication of conditioned medium or AF64A was not removed during the 72 h observation period. Controls received an equivalent amount of vehicle and were rinsed correspondingly.
Staurosporine was dissolved in DMSO (10 mM stock solution) and diluted with PBS to give the final concentrations of 100 and 300 nM in culture. The vehicle-treated cultures received the same amount of DMSO (in PBS) present in the highest dose of staurosporine.
For OGD medium was removed from the cultures and preserved. Cultures were rinsed twice with PBS, then subjected to OGD for 120 min in a balanced salt solution at pO 2 Ͻ 2 mm Hg, followed by replacement of the preserved medium as described previously (39) . For standardization of the neuronal damage, the sister cultures were treated with an excess of glutamate (5 mM; full kill). To differentiate between the excitotoxic and apoptotic components of OGD as described previously (36), cells were treated with the NMDA antagonist MK-801 (10 M) 30 min prior to OGD (120 or 180 min).
Caspase inhibition
For caspase inhibition the general caspase inhibitor Z-VAD-FMK (100 M) dissolved in DMSO (0.2% final concentration) was used. In the AF64A model Z-VAD-FMK or vehicle containing the corresponding amount of DMSO was added 1 h before as well as 24 and 48 h after AF64A application. In the model of OGD plus MK-801 pretreatment Z-VAD-FMK was added at the beginning of reoxygenation and 24 h later.
Treatment with melatonin, PBN, and DMTU
Melatonin was dissolved in a 40% ethanol solution, then diluted with medium to a 20 mM stock solution. It was applied to the cell cultures in a final concentration of 0.01 to 2.0 mM. Melatonin was added 1 or 2 h before AF64A, 1 h before staurosporine and 1 h before OGD. The final concentration of ethanol per well did not exceed 0.01% at all melatonin concentrations used. The vehicle-treated control cultures received the equal amount of ethanol (0.01%). PBN (dissolved in DMSO) and DMTU (dissolved in PBS) were added 1 h before AF64A or staurosporine. The final concentration of DMSO per well did not exceed 0.2%. Vehicle-treated cultures received the equal amount of DMSO.
Cell viability assays
Neuronal injury was quantitatively assessed by the measurement of LDH in the medium (40) at 24, 48, and 72 h after AF64A or staurosporine application and at 24 and 48 h after OGD. As a second measure the MTT assay (41) , based on the cleavage of the yellow tetrazolium salt MTT to purple formazan by mitochondrial enzymes in metabolically active cells was performed 72 h after addition of AF64A or staurosporine.
Measurement of oxidative stress
The extent of oxidative stress was assessed by the amount of malondialdehyde formed in the cell cultures exposed to AF64A or staurosporine. For this purpose, medium was removed and cells were washed with PBS and harvested by scraping off mechanically at various time points after the addition of staurosporine, AF64A, melatonin, or the corresponding vehicle. In addition, the effect of the antioxidants melatonin, PBN, and DMTU on the formation of malondialdehyde induced by AF64A or staurosporine was investigated. The concentration of malondialdehyde was measured according to the method of Wong et al. (42) .
Data analyses
Data are shown as means Ϯ se. To avoid possible variations of the cell cultures depending on the quality of dissection and seeding procedures, data were pooled from two to three dissections. For statistical analyses the one-way ANOVA was followed by Tukey post hoc tests.
RESULTS
Morphological differences in neuronal cell death after AF64A treatment or OGD
In Fig. 1 , representative phase contrast photomicrographs of primary neuronal cultures under control conditions after AF64A exposure and after OGD are summarized. AF64A triggered morphological signs of apoptosis including degeneration of neurites, shrinkage of cell bodies, and fragmentation in condensed particles, whereas after OGD (120 min) the occurrence of blown up cell bodies typical for necrosis prevailed.
Effect of melatonin treatment on cell viability in native primary neuronal cultures
A single dose treatment of primary neuronal cultures with melatonin (dose range of 0.01 to 0.5 mM) induced a significant increase in LDH release after 72 h as compared to vehicle-treated cultures ( Table  1) . This effect was not obvious after 24 h, started after 48 h, and reached significance 72 h after a single exposure to melatonin (0.05 and 0.5 mM). The increase in LDH release was not due to the addition of small amounts of ethanol, since vehicletreated cells received the equivalent amount of eth- anol. Moreover, a dose-dependent increase in the concentration of malondialdehyde was observed 24 h after the addition of melatonin (0.5 to 2.0 mM) to native cortical cells, indicating the occurrence of lipid peroxidation (Fig. 2) .
Effect of melatonin on staurosporine-induced apoptotic neuronal cell death
When applied to cortical neuronal cultures, staurosporine increased LDH release and reduced MTT metabolism dose and time dependently. A marked increase in LDH release was already detectable at 24 h after exposure. Since 5 h after staurosporine application the production of mitochondrial reactive oxygen species by staurosporine had initially been reported in chick embryonic neurons (43), we also assessed lipid peroxidation in our model. At this early time point the level of malondialdehyde transiently increased from 0.116 Ϯ 0.004 M in vehicletreated sister cultures (nϭ10) to 0.224 Ϯ 0.009 M after treatment with 300 nM staurosporine (nϭ8; PϽ0.001). Pretreatment with 0.1 mM and 0.5 mM melatonin significantly reduced the staurosporineinduced malondialdehyde formation to 0.159 Ϯ 0.009 M (nϭ6) and 0.165 Ϯ 0.004 M (nϭ10), respectively (PϽ0.001 vs. 300 nM staurosporine). In spite of this antioxidative effect, treatment with melatonin (0.1 or 0.5 mM) did not prevent staurosporine-induced neuronal cell death. In contrast, at the higher dose range melatonin appeared to aggravate LDH release or loss of metabolic activity at all time points investigated ( Table 2) .
Effect of melatonin treatment on AF64A-induced neurodegeneration
Primary neuronal cell cultures from cortex were exposed to AF64A. As reported previously, the neuronal cells reacted to AF64A with a delayed dose-and time-dependent reduction in cell viability as quantified by LDH release and MTT assay. At all doses of AF64A applied (10 -80 M), LDH release was not detectable for up to 24 h. LDH in the medium started to rise after 48 h, with the most pronounced increase on day 3 of treatment ( Fig. 3; 44) . Likewise, even at the highest dose of AF64A, MTT metabolism was not decreased before 16 h, but then gradually declined to reach a minimum at 72 h after toxin application. Comparable results were obtained when the exposure to AF64A was reduced to 5 h by removal of the AF64A-containing medium and replacement by pooled preconditioned medium (data not shown).
To differentiate whether the apoptotic neuronal cell death induced by AF64A is caspase dependent or independent, the unspecific caspase inhibitor Z-VAD-FMK was used. Treatment of cortical cells with 100 M Z-VAD-FMK before and during AF64A exposure completely prevented the significant increase in LDH release occurring 48 h and 72 h after AF64A application (Fig. 4) .
Pretreatment of cortical cultures with melatonin (0.1 and 0.5 mM 2 h before AF64A addition) did not attenuate the AF64A-induced LDH release or prevent the reduction in MTT metabolism (Fig. 3 and  Fig. 5 ). In contrast, AF64A-induced LDH release tended to be higher after pretreatment with melatonin. Potentiation of the neurotoxic effect was also evident at the low dose of AF64A (10 M), when only a slight increase in LDH release was detected (Fig.  3) . Comparable results were obtained when melatonin was added 1 h before AF64A (data not shown).
To investigate whether oxidative stress plays a role in the AF64A-induced neuronal damage and, if so, whether melatonin as a free radical scavenger is able to avoid oxidative damage in this model, we measured the extent of lipid peroxidation. In primary neuronal cultures of cortex, the application of AF64A was followed by an increase in malondialdehyde, which started after 10 h, was most pronounced after 24 h, and was no longer detectable after 48 h. At this time point apoptotic cell death was evident according to LDH release, morphological changes, and DNA laddering (35, 44) . The addition of melatonin (0.1 mM) 1 h before AF64A significantly reduced the increase in malondialdehyde (Fig. 6) .
Effect of PBN and DMTU on AF64A-and staurosporine-induced neurodegeneration
To obtain additional information on the involvement of free radicals, two other general antioxidants, DMTU and the spin trap PBN, were tested. Neither antioxidant prevented the increase in LDH release 72 h or 48 h after application of AF64A or staurosporine, respectively (Table 3 A, B) . In contrast to melatonin, DMTU (1 or 10 mM) and PBN (0.1 or 1.0 mM) had no significant effect on the LDH release from native cells within 72 h (Table 1) . Comparable to melatonin, both PBN and DMTU completely prevented the increase in malondialdehyde observed 24 h or 5 h after addition of AF64A or staurosporine, respectively (Table 3A, B) .
Effect of melatonin on OGD-induced neuronal cell death
Exposure of primary cultures of rat cortical neurons to OGD for 120 min resulted in a considerable increase in the release of LDH within 24 h to an extent almost comparable to that induced by an excess of glutamate (full kill). Melatonin dose-dependently reduced the release of LDH. A significant reduction was achieved at a dose range of 0.5 mM, whereas at higher doses the neuroprotective effect vanished (Fig. 7) .
On the other hand, neuroprotection by melatonin was not achieved when OGD was performed in the presence of the NMDA receptor antagonist MK-801, thereby blocking the excitotoxic component of hypoxia (36). When cells were exposed to OGD for 2 h, MK-801 reduced the release of LDH to 40.6 Ϯ 4.0% and 53.6 Ϯ 3.7% 24 and 48 h after OGD, respectively. The protective effect of MK-801 was considerably higher than that achieved by 0.5 mM melatonin (reduction to 78.2Ϯ7.9% and 75.7Ϯ2.0, respectively; Table 4 ). When OGD was prolonged to 3 h, MK-801 was less effective (reduction of LDH release to 79.5Ϯ4.1%, both after 24 and 48 h) and no further reduction was achieved by addition of melatonin (0.1 and 0.5 mM), whereas additional treatment with the caspase inhibitor Z-VAD-FMK provided a further 
DISCUSSION
The present study provides new insight into the neuroprotective potential of melatonin. Our results confirm the neuroprotective efficacy of melatonin in models of neuronal necrosis associated with an accumulation of free radicals. In agreement with previous findings (25) , OGD-induced cortical neuronal cell death was prevented by melatonin at least in part. In contrast, no evidence was found indicating the efficacy of melatonin in the case of apoptotic neuronal cell death. This has been demonstrated in three different models of apoptotic neuronal cell death. All three models depend on the activation of caspases, as has been demonstrated previously (36) and/or in the present study, but differ in the mechanisms and time course leading to apoptosis. In neuronal cell death associated with apoptosis induced by AF64A or staurosporine, melatonin was not neuroprotective. Moreover, a lack of neuroprotection by melatonin was found in regard to the apoptotic component of OGD. Neuronal cell death triggered by ischemia traditionally is regarded as necrosis. Increasing evidence suggests that apoptosis may also contribute to brain damage resulting from ischemic insults and the apoptotic death can be unmasked with glutamate antagonists (36, 45) . In the present study, we demonstrated that melatonin was no longer neuroprotective in OGD when the excitotoxic, NMDA receptor-mediated hypoxic injury was prevented by treatment with the glutamate antagonist MK-801 and, consequently, apoptotic cell death prevailed. The limited effect of melatonin in hypoxia without blockade of NMDA receptors (Table 3 and Fig. 7 ) might be explained by the protective effect of melatonin restricted to the necrotic component of ischemic cell death only. This is in accordance with the observation that trolox, an antioxidant analog to vitamin E, prevented necrosis but unmasked apoptosis in cultured neurons subjected to oxygen deprivation (45) .
Depending on the model for cell death, the variable efficacy of melatonin requires the use of a variety of different models in order to obtain a profound insight into the neuroprotective potential of this compound. We therefore chose three models of apoptotic neuronal cell death that differ considerably regarding the time course in which neurodegeneration develops. The unique feature in the AF64A model is a delayed onset of neuronal cell death in the cultures within 72 h, with no morphological changes and no increase in LDH release 24 h after exposure. In contrast, neuronal apoptosis induced by staurosporine is fully visible within 24 h. OGD induced apoptosis is fully developed after 24 h and the portion of total damage remains stable for up to 48 h (Fig. 8) . Previous experience indicates that melatonin attenuates neuronal apoptosis in the case of 6-OHDA-, ␤-amyloid-, and kainate-induced cell damage in vitro and in vivo. 6-OHDA has been demonstrated to trigger apoptosis in low concentrations in cultured dopaminergic neurons, cerebellar granule neurons, and PC12 cells within 18 -24 h (46 -48) , whereas at higher concentrations of 6-OHDA cells die by necrosis within 6 h (47). However, it has to be considered that the mechanism by which 6-OHDA damages cells involves the formation of hydrogen peroxide, superoxide, and free radicals (49) , which can be scavenged by melatonin. Oxygen free radicals and increased sensitivity to excitotoxicity, which are antagonized by melatonin, have been related to the cytotoxic properties of ␤-amyloid. The appearance of both apoptotic and necrotic cell death has been described for ␤-amyloid-induced toxicity depending on the cell type (50 -52) . Moreover, the cytoprotective properties of melatonin against ␤-amyloid have been explained by the in vitro ability of melatonin to modify the secondary structure of ␤-amyloid and to inhibit the formation of amyloid fibrils (53) . In vivo evidence is available that melatonin protects against DNA damage, which was observed in the hippocampus 48 and 72 h after intraperitoneal administration of kainate to rats (54) . The delayed onset of apoptotic cell damage excludes a direct neurotoxic action of kainate and thus a direct prevention of apoptosis by melatonin. More likely, the protective effect against delayed apoptosis in response to kainate may have resulted from the prevention of seizure activity by treatment with melatonin (9, 10, 14) . Kainate-induced apoptotic cell death in hippocampal neurons also was prevented when seizures were blocked by diazepam (55) . The neuroprotective effect of melatonin against kainate-induced brain damage is believed to be related to its oxygen radical scavenging properties as well as its antiepileptic and GABA receptor regulatory actions (10) . Moreover, after intrastriatal injection of kainate in the rat, melatonin reduced delayed apoptotic neuronal death in adjacent cortex but not in the striatum, again excluding a direct effect of melatonin on apoptosis (56) . Up-regulation of the glutathione antioxidative defense system by melatonin has been suggested as a mechanism for reducing neuronal death caused by excitotoxicity and for preventing the kainate-induced damage from spreading to adjacent brain regions (21, 56) .
In the present study, evidence has been obtained that melatonin accelerates neuronal cell death in cultures. When added to native primary neuronal cultures, melatonin per se decreased cell viability as demonstrated by a significant increase in LDH within 72 h. This adverse effect of melatonin has not been documented before. Either no values for control cultures treated with melatonin were presented or the observation period was 24 h or shorter. At this time point, however, no change in cell viability had yet appeared in our experiments. No changes in LDH release within 72 h were detected in response to PBN and DMTU. The slight cytotoxicity of melatonin may indicate the presence of a prooxidant activity associated with the antioxidant melatonin. This phenomenon has been described for melatonin and other antioxidants including estrogen and vitamin C (57-60). The increase in malondialdehyde induced by melatonin also underlines the prooxidant potential of melatonin. According to Reiter (3) , melatonin is believed to work via electron donation in detoxifying the ⅐ OH radical. In so doing, melatonin must itself become a radical, the indolyl cation radical. However, indole radical cations have been shown to react with oxygen, giving rise to indoxyls via peroxy radical intermediates. The formation of the radical cation of melatonin has been made responsible, e.g., for the enhancement of vitamin E consumption induced by oxidative stress in red blood cells (61) . Medina-Navarro et al. (60) also suggested the formation of secondary oxidation products as a possible mechanism for the prooxidant property of melatonin. A prooxidant action would also explain our findings that melatonin aggravated the AF64A-and staurosporine-induced LDH release, and the protective effect in OGD started to vanish in the higher dose range. Similarly, melatonin potentiated the neurotoxicity of methamphetamine in rats (62) . These findings, however, would implicate that caution is necessary, when melatonin is used therapeutically in higher concentrations in humans. In this respect, the report of proconvulsant effects of oral melatonin in neurologically disabled children is intriguing (63) .
Various mechanisms are discussed by which melatonin mediates its neuroprotection (see beginning of article). However, none of these mechanisms was able to interfere with the progression of the caspasedependent apoptotic neuronal cell death in the three applied models. This also refers to the antioxidant potential of melatonin. Although the increase in malondialdehyde during the first 24 h after application of AF64A was blocked by melatonin, this blockade did not result in the avoidance of apoptotic cell loss. Thus, the presence of oxidative stress in the AF64A model, which has been demonstrated in vitro in the present study (Fig. 6 ) and in vivo after intracerebroventricular administration of AF64A (64), does not appear to initiate and/or support the progression of programmed cell death in this specific model. This has been demonstrated in the staurosporine-induced apoptosis and may also refer to the apoptotic component of OGD. The minor role of free radicals in these models is further underscored by the inefficacy of PBN and DMTU in preventing AF64A and staurosporine-induced cell death in spite of the complete prevention of the formation of malondialdehyde. In the case of excitotoxicity, melatonin prevented both the increased formation of lipid peroxidation products and the neuronal damage, as has been shown after hippocampal injection of quinolinic acid (65) .
In conclusion, the present data suggest that the neuroprotectiveness of melatonin strongly depends on the cause of neuronal cell death. As demonstrated in three different models of neuronal caspase-dependent apoptosis, the progression of apoptotic neuronal cell death was not inhibited by melatonin, in contrast to its effect on neuronal necrosis. If the formation of free radicals or the excess of excitotoxins are the major mechanisms responsible for the initiation of the cell death program, however, melatonin might be protective. In addition to this beneficial effect, evidence for the exaggeration of neuronal damage by melatonin has been obtained. Melatonin might be considered an endogenous neuroprotective factor useful for the pharmacological treatment of neurodegeneration produced by glutamate excitotoxicity and/or oxidative stress, such as brain ischemia or epilepsia. In contrast, a therapeutic potential of melatonin in neurodegeneration mainly associated with the apoptotic type of neuronal cell death is questioned.
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